ClinicalTrials.gg
RecruitingNCT07266181Updated Dec 24, 2025

Safety and Efficacy of CD19 Chimeric Antigen Receptor T-Cell (CAR-T) in the Treatment of Refractory Membranous Nephropathy

A Phase 1 interventional study of All patients will receive CD19 CAR-T cell therapy on the basis of standard symptomatic and supportive treatment. in Refractory Membranous Nephropathy, sponsored by The First Affiliated Hospital of Air Force Medicial University. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-24.

Sponsored by The First Affiliated Hospital of Air Force Medicial University · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
5
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 60 studies in Glomerulonephritis, Membranous with a site in China — 29 open to participants now, 37 under way, 10 of them phase 3. Glomerulonephritis, Membranous · China.

Planned enrollment
48th of 50
5 · median 77
Started
2025
with 7 others
Phase 1
7 of 60
6 open now
Primary completion
2027-07
later than 20 of 36 live
Registered
51st of 60
by date

Among the 60 studies in Glomerulonephritis, Membranous with a site in China, this one is the 48th largest by planned enrollment of the 50 interventional ones that give a count, is one of 8 that started in 2025, is one of 7 in phase 1, reaches primary completion later than 20 of the 36 other live ones, and was the 51st registered.

Glomerulonephritis, Membranous

146 studies on the registry are indexed under Glomerulonephritis, Membranous; 60 are open to participants now.

Browse Glomerulonephritis, Membranous studies →

Open to participants now

29 of the 60 studies in Glomerulonephritis, Membranous with a site in China are open now. Recruiting first, the newest first:

23 more — sign in →

All 29 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 41 Glomerulonephritis, Membranous studies recruiting now, 14 (34%) set no upper age limit and 13 (32%) stop at 75 or younger; 8 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies in Glomerulonephritis, Membranous with a site in China, or all of them as a file.
02

Study summary

This study is a single-center, prospective, exploratory Phase I clinical trial initiated by the team led by Associate Professor He Lijie from the Department of Nephrology, Xijing Hospital.

Prior to receiving CAR-T cell therapy, patients will undergo lymphodepletion chemotherapy with cyclophosphamide (fludarabine will be added if necessary). After prophylactic administration of antihistamines and acetaminophen, patients will be infused with CD19 CAR-T cells at a dose of 1×10⁶ cells/kg.

In the subsequent 2 weeks, patients will be hospitalized for monitoring of vital signs and adverse reactions. The planned follow-up duration of this study is 1 years.

03

Conditions studied

  • Refractory Membranous Nephropathy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed as primary membranous nephropathy (PMN) by renal .
  • Classified as moderate-risk or high-risk membranous nephropathy (rMN).
  • Moderate-risk rMN is defined as: ≥ 90 ml/min/1.73m² AND 24-hour urinary protein > 3.5g/d, with a reduction of no more than 50% within 6 months of receiving renin-angiotensin system inhibitor (RASi) therapy.
  • High-risk rMN is defined as meeting one of the following:

    1. eGFR \< 60 ml/min/1.73m² and/or persistent proteinuria > 8g/d for more than 6 months.
    2. Normal eGFR with proteinuria > 3.5g/d and ≤50% reduction after 6 months of RASi therapy, PLUS at least one of the following: Serum albumin \< 25g/L; PLA2R antibody > 50 RU/mL; Urinary α1-microglobulin > 40 μg/min; Urinary IgG > 1 μg/min; Urinary β2-microglobulin > 250 mg/d; IgG/albumin clearance ratio > 0.20.
  • Diagnosis of rMN requires failure of adequate therapy (≥6 months of +cyclophosphamide, CNI, or rituximab), defined by any of the following: persistent high-titer anti-PLA2R antibody; for antibody-negative patients, persistent nephrotic syndrome (protein >3.5g/d, albumin \<30g/L); \<50% reduction in proteinuria.
  • Age ≥ 18 years.
  • Adequate organ function, defined as:

    1. Renal: eGFR ≥ 30 ml/min/1.73m².
    2. Hepatic: and AST ≤ 2.5 x ; Total ≤ 1.5 x ULN.
    3. Cardiac: ≥ 50%; Class I or II; No significant arrhythmias requiring intervention; No major cardiovascular events within the past 6 months.
    4. Respiratory: SpO2 > 92% on room air.
  • Ability to understand and willingness to sign an Form.

Exclusion criteria

Exclusion Criteria:

  • Secondary membranous nephropathy (e.g., due to SLE, , drugs, infection).
  • Active infection requiring IV antibiotics, active tuberculosis, or positive viral serology indicating active infection, including:

    1. : HBsAg (+) and/or HBcAb (+) with detectable HBV DNA.
    2. : HCV Ab (+) with detectable HCV RNA.
    3. Ab (+).
    4. Active EBV or CMV infection (IgM+ or DNA above normal).
    5. Positive syphilis (Treponema pallidum) antibody (requires evaluation for active infection).
  • Severe uncontrolled comorbidities, including:

    1. Uncontrolled hypertension (persistent SBP > 160 mmHg or DBP > 100 mmHg).
    2. Uncontrolled diabetes ( > 8% or random glucose ≥11.1 mmol/L) or diabetic nephropathy.
    3. Symptomatic deep vein thrombosis or pulmonary embolism within the past 6 months.
    4. Active peptic ulcer or gastrointestinal bleeding within the past 6 months.
    5. Severe congenital or acquired immunodeficiency.
    6. Severe CNS diseases (e.g., catastrophic APS, uncontrolled epilepsy).
    7. End-stage organ failure not attributable to PMN.
  • History of malignancy within the past 5 years, except for adequately treated non-melanoma skin cancer, cervical carcinoma in situ, or thyroid cancer.
  • Specific treatment history or plans, including:

    1. Prior receipt of any cell therapy (e.g., MSCs, ).
    2. Major surgery within 24 weeks before or planned within 24 weeks after enrollment.
    3. Planned kidney transplantation within 3 years.
    4. History of substance abuse.
  • Participation in another interventional clinical trial within 3 months prior to enrollment.
  • Pregnant or lactating women.
  • Inability to understand the study or provide (e.g., severe dementia, mental illness).
  • Any other condition deemed by the investigator to increase risk, interfere with assessment, or affect compliance.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
5 participants (estimated)

Study arms

  • Other
    To preliminarily evaluate the safety and efficacy of CD19 CAR-T in refractory membranous nephropathy

    Other: All patients will receive CD19 CAR-T cell therapy on the basis of standard symptomatic and supportive treatment.

Interventions

  • OtherAll patients will receive CD19 CAR-T cell therapy on the basis of standard symptomatic and supportive treatment.

    Prior to receiving CAR-T cell therapy, patients will undergo lymphodepletion chemotherapy with cyclophosphamide (fludarabine will be added if necessary). After prophylactic administration of antihistamines and acetaminophen, patients will be infused with CD19 CAR-T cells at a dose of 1×10⁶ cells/kg.

06

What researchers measure

Primary outcomes

  1. Incidence of DLT in rMN subjects after a single infusion of CD19 CAR-T cells

    Definition: The DLT evaluated in this study is assessed within two time windows: 28 days (Day 0 to Day 28) and 3 months (Day 28 to Month 3) after CAR-T cell infusion. These time windows are selected based on the typical timeline of CAR-T cell expansion, activity, and potential occurrence of major toxicities in vivo. The determination of DLT must meet all the following criteria:1.DLT must be an adverse event judged by the investigator as probably or definitely related to CAR-T cell infusion, and cannot be attributed to underlying diseases, comorbidities, or toxicities from concomitant medications;2.The adverse event must reach a severity grade of ≥ Grade 3 (per CTCAE v5.0) or ≥ Grade 3 specific toxicity grading criteria (e.g., IEC-HS grading).

    Time frame: 28 days and 3 months after infusion

  2. Incidence of AE in rMN subjects after a single infusion of CD19 CAR-T cells

    Severity grading is based on the Common Terminology Criteria for Adverse Events (CTCAE) v5.0: Grade 1: Mild; asymptomatic or mild symptoms; only clinically or diagnostically detectable; no treatment required. Grade 2: Moderate; requires minor, local, or non-invasive treatment; limitation in age-appropriate instrumental activities of daily living. Grade 3: Severe or medically significant but not immediately life-threatening; results in hospitalization or prolongation of existing hospitalization; disabling; limitation in self-care activities of daily living. Grade 4: Life-threatening; requires urgent treatment. Grade 5: Death related to complications.

    Time frame: 12 months after infusion

Secondary outcomes

  1. Overall response rate (CR+PR) in rMN subjects after cell infusion

    1. Definition of rMN CR: Disappearance of the patient's clinical symptoms and signs; urine protein reduced to \<0.3 g/day or UACR \<300 mg/g; with normal levels of serum albumin (ALB) and serum creatinine (Scr). 2. Definition of rMN PR: Improvement in clinical symptoms and signs; urine protein decreased by more than 50% compared with baseline, and reduced to 0.3-3.5 g/day or UACR 300-3500 mg/g.

    Time frame: Week 2, Month 1, Month 2, Month 3, Month 6, Month 9, Month 12, Month 18 (if applicable), Month 24 (if applicable) after infusion

  2. Proportion of rMN subjects achieving CR after cell infusion

    Definition of rMN CR: Disappearance of the patient's clinical symptoms and signs; urine protein reduced to \<0.3 g/day or UACR \<300 mg/g; with normal levels of serum albumin (ALB) and serum creatinine (Scr).

    Time frame: Week 2, Month 1, Month 2, Month 3, Month 6, Month 9, Month 12, Month 18 (if applicable), Month 24 (if applicable) after infusion

  3. Proportion of rMN subjects achieving PR after cell infusion

    Definition of rMN PR: Improvement in clinical symptoms and signs; urine protein decreased by more than 50% compared with baseline, and reduced to 0.3-3.5 g/day or UACR 300-3500 mg/g.

    Time frame: Week 2, Month 1, Month 2, Month 3, Month 6, Month 9, Month 12, Month 18 (if applicable), Month 24 (if applicable) after infusion

  4. rMN recurrence after cell infusion

    Definition of rMN recurrence: After NR or PR, the patient's urine protein rises again to \>3.5 g/day or UACR \>3500 mg/g; frequent recurrence is defined as more than 2 recurrences within 6 months or more than 4 recurrences within 12 months.

    Time frame: Week 2, Month 1, Month 2, Month 3, Month 6, Month 9, Month 12, Month 18 (if applicable), Month 24 (if applicable) after infusion

  5. eGFR

    Change in eGFR from baseline in rMN subjects after a single infusion of CD19 CAR-T cells. Estimated glomerular filtration rate, calculated using the CKD-EPI 2021 formula

    Time frame: Week 2, Month 1, Month 2, Month 3, Month 6, Month 9, Month 12, Month 18 (if applicable), Month 24 (if applicable) after infusion

  6. Urine protein

    Change in urine protein from baseline in rMN subjects after a single infusion of CD19 CAR-T cells, 24-hour urine protein quantification

    Time frame: Week 2, Month 1, Month 2, Month 3, Month 6, Month 9, Month 12, Month 18 (if applicable), Month 24 (if applicable) after infusion

  7. UACR

    Change in UACR from baseline in rMN subjects after a single infusion of CD19 CAR-T cells, Random urine

    Time frame: Week 2, Month 1, Month 2, Month 3, Month 6, Month 9, Month 12, Month 18 (if applicable), Month 24 (if applicable) after infusion

  8. anti-PLA2R antibody

    Change in serum anti-PLA2R antibody from baseline in rMN subjects after a single infusion of CD19 CAR-T cells. Venous blood

    Time frame: Week 2, Month 1, Month 2, Month 3, Month 6, Month 9, Month 12, Month 18 (if applicable), Month 24 (if applicable) after infusion

  9. Scr, CysC

    Change in serum renal function from baseline in rMN subjects after a single infusion of CD19 CAR-T cells.Venous blood

    Time frame: Week 2, Month 1, Month 2, Month 3, Month 6, Month 9, Month 12, Month 18 (if applicable), Month 24 (if applicable) after infusion

  10. Routine blood test

    Change in blood cells in rMN subjects after a single infusion of CD19 CAR-T cells.Venous blood

    Time frame: Week 2, Month 1, Month 2, Month 3, Month 6, Month 9, Month 12, Month 18 (if applicable), Month 24 (if applicable) after infusion

  11. CRP

    Change in CRP in rMN subjects after a single infusion of CD19 CAR-T cells.Venous blood

    Time frame: Day 2, Day 7, Day 10 or 14, Day 21, Day 28 (1 month) after infusion

  12. Serum complements C3, C4

    Change in complements in rMN subjects after a single infusion of CD19 CAR-T cells.

    Time frame: Week 2, Month 1, Month 2, Month 3, Month 6, Month 9, Month 12, Month 18 (if applicable), Month 24 (if applicable) after infusion

  13. IgE、IgA、IgG、IgM

    Change in immunoglobulins in rMN subjects after a single infusion of CD19 CAR-T cells.

    Time frame: Week 2, Month 1, Month 2, Month 3, Month 6, Month 9, Month 12, Month 18 (if applicable), Month 24 (if applicable) after infusion

  14. CAR copy number

    Change in CAR copy parameters in rMN subjects after a single infusion of CD19 CAR-T cells

    Time frame: Day 2, Day 5, Day 7, Day 10 or 14, Day 21, Day 28 (1 month), Month 2, Month 3, Month 6, Month 9, Month 12, Month 18 (if applicable), Month 24 (if applicable) after infusion

  15. Ferritin level

    Change in ferritin in rMN subjects after a single infusion of CD19 CAR-T cells

    Time frame: Day 2, Day 7, Day 10 or 14, Day 21, Day 28 (1 month) after infusion

  16. Cytokine panel

    Change in cytokines in rMN subjects after a single infusion of CD19 CAR-T cells

    Time frame: Day 2, Day 7, Day 10 or 14, Day 21, Day 28 (1 month) after infusion

  17. Peripheral blood lymphocyte subset count

    Change in peripheral blood lymphocyte subsets in rMN subjects after a single infusion of CD19 CAR-T cells

    Time frame: Day 2, Day 5, Day 7, Day 10 or 14, Day 21, Day 28 (1 month) after infusion

  18. The surface of peripheral blood B cell subsets

    Expression level of CD19 on the surface of peripheral blood B cell subsets in rMN subjects after a single infusion of CD19 CAR-T cells

    Time frame: Day 2, Day 5, Day 7, Day 10 or 14, Day 21, Day 28 (1 month) after infusion

07

Study locations

1 of 1 sites recruiting
  • Department of Nephrology, Xijing Hospital
    Xi'an, China 710012, China
    Recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2025 (actual). Primary completion is estimated for Jul 2027, 19 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2025
First posted
Dec 5, 2025
StartActual
Dec 8, 2025
Primary completionEst.
Jul 31, 2027
CompletionEst.
Jul 31, 2028
Last update
Dec 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07266181
Lead sponsor
The First Affiliated Hospital of Air Force Medicial University
Responsible party
Li Jipeng (Research associate, The First Affiliated Hospital of Air Force Medicial University) — Principal investigator
First posted
Dec 5, 2025
Start date
Dec 8, 2025
Primary completion
Jul 31, 2027 (estimated)
Completion
Jul 31, 2028 (estimated)
Last update
Dec 24, 2025

Study contacts

Jipeng Li
Contact
shaona@ldy.edu.rs
8684775197

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion